Global Dry Eye Syndrome Market research report, by type (evaporative, aqueous), by diagnosis (schirmer test, eye exam), treatment (nutritional supplements, surgery), distribution channel (hospital pharmacies) end user (hospitals) - global forecast till 2027
ID: MRFR/Pharma/4139-HCR | February 2021 | Region: Global | 90 pages
Market Scenario
Global dry eye syndrome market is expected to advance with an approximate CAGR of 6.6% during the forecast period.
Tears provide lubrication, limits the risks of eye infections, washes away the foreign matter, thus, are helpful in keeping the surface of the eyes smooth and clear. Dry eye syndrome is a medical condition in which eyes’ lubrication is hindered by the unavailability of tears. Under normal condition, during excessive production, tears flow into the small drainage ducts of the inner corners of the eyes, followed by draining back into the nose. Sometimes when the production of tears and drainage is not balanced, it can result into dry eye syndrome. Eye redness, sensitivity to light, watery eyes, eye fatigue are some of the common symptoms of the disease. Increasing geriatric population, rising prevalence of diseases like diabetes, rheumatoid arthritis, and others are estimated to be the major drivers for the market growth. According to the World Health Organization in 2016, approximately 422 million adults were globally affected by diabetes in 2014, as compared to 108 million in the 1980’s. Moreover, in 2014, it was estimated that the global prevalence of diabetes was estimated to be around 8.5%. Additionally, rising per capita healthcare expenditure, and changing lifestyle boosts the market. However, factors like stringent FDA drug approvals, lack of skilled ophthalmologists, and low per capita healthcare expenditure in the middle and low income countries are restraining the market.
Intended Audience
- Pharmaceutical Companies
- Biotechnological Institutes
- Government And Private Laboratories
- Research And Development (R&D) Companies
- Medical Research Laboratories
- Market Research and Consulting Service Providers
Figure 1: Global Dry Eye Syndrome Share, By Region
Sources: WHO, Mayo Foundation for Medical Education and Research, National Health Service, National Eye Institute, Australian Institute of Health and Welfare, annual reports, press release, white paper, and company presentation
Segmentation
The global dry eye syndrome is segmented on the basis of the type, diagnosis, treatment, distribution channel and end user.
On the basis of the type, the market is segmented into evaporative dry eye syndrome aqueous dry eye syndrome, and others. On the basis of the diagnosis, the market is categorized into Schirmer test, eye exam, and others. On the basis of the treatment, the market is segmented into nutritional supplements, serum eye drops, lubricant eye drops, anti-inflammatory drugs segments, surgery, and others. The lubricant eye drops segment is sub-segmented into oily tear eye drops, ointments, preservative-free drops, and others. The anti-inflammatory drugs segments segement is sub-segmented into tetracyclines, corticosteroids, and others. The surgery segment is sub-segmented into punctal occlusion, intense pulsed light therapy, and others. On the basis of distribution channel, the market is segmented into hospital pharmacies, retail pharmacies, online pharmacies, and others. On the basis of the end users, the market is segmented into hospitals, clinics, home care, and others.
Key Players in dry eye syndrome market
The key players for the global dry eye syndrome are Allergan (Republic of Ireland), Novartis AG (Switzerland), Otsuka Pharmaceutical Co. Ltd. (Japan), Valent Pharmaceuticals (Canada), Johnson & Johnson Vision (U.S.), Acadia Pharmaceutical (U.S.), Allostera Pharma (Canada), I-Med Pharma Inc. (Canada), Santen Pharmaceuticals Co. Ltd., (Japan), AFT pharmaceuticals (New Zealand), Novaliq GmBh (Germany), Auven therapeutics (U.S.), and others.
Research Methodology
Sources: WHO, Mayo Foundation for Medical Education and Research, National Health Service, National Eye Institute, Australian Institute of Health and Welfare, annual reports, press release, white paper, and company presentation
Regional Analysis
America dominates the global dry eye syndrome market. This can be attributed to the presence of a well-developed healthcare sector and a large patient population. Moreover, increasing healthcare expenditure boosts the growth of the American market. Additionally, the presence of the major market players like Johnson & Johnson Vision, Auven therapeutics, Acadia Pharmaceutical, and others within the region fuels the market growth.
Europe is the second largest dry eye syndrome market owing to increasing availability of funds for research, a well-developed healthcare sector, huge patient pool and growing geriatric population. According to the Saga in 2017, approximately 20% of people living in the U.K suffer from dry eye syndrome. Moreover, it was estimated that one in three people who age 65 or more within the region are diagnosed with this disease.
Asia Pacific is the fastest growing region for the market due to the presence of economies like India, China, Australia, and others. Moreover, huge patient population, rising healthcare expenditure boosts the market growth. According to the Australian Institute of Health and Welfare, the total Australian health expenditure from 2015 to 2016 was estimated to be about USD 170.4 billion.
The Middle East & Africa has the least share in the global dry eye syndrome due to the presence of poor economies, low per capita healthcare expenditure, stringent government policies, especially within the African region. The Middle East holds a majority of the market due to a well-developed healthcare sector and huge healthcare expenditure by the developed economies like Dubai, Kuwait, Dubai, and others.
Frequently Asked Questions (FAQ) :
The outlook of the global dry eye syndrome market looks flourishingly growing.
The global dry eye syndrome market is projected to grow at approximately 6.6% CAGR during forecast period (2017-2023).
Supportive government initiatives and funding.
North America holds the largest share in the global dry eye syndrome market followed by Europe and Asia Pacific, respectively.
SORIN Group (Europe), LEPU MEDICAL (UK), MEDICO S.p.A. (Europe), Abbott. (US), Medtronic (US), Boston Scientific Corporation (US), OSCOR Inc. (US), and BIOTRONIK (Germany), are some of the major players operating in the dry eye syndrome market.
TABLE OF CONTENT
Chapter 1. Report Prologue
Chapter 2. Market Introduction
2.1 Definition
2.2 Scope of the Study
2.2.1 Research Objective
2.2.2 Assumptions
2.2.3 Limitations
Chapter 3. Research Methodology
3.1 Introduction
3.2 Primary Research
3.3 Secondary research
3.4 Market Size Estimation
Chapter 4. Market Dynamics
4.1 Drivers
4.2 Restrains
4.3 Opportunities
4.4 Challenges
4.5 Macroeconomic Indicators
4.6 Technology Trends & Assessment
Chapter 5. Market Factor Analysis
5.1 Porter’s Five Forces Analysis
5.1.1 Bargaining Power of Suppliers
5.1.2 Bargaining Power of Buyers
5.1.3 Threat of New Entrants
5.1.4 Threat of Substitutes
5.1.5 Intensity of Rivalry
5.2 Value Chain Analysis
5.3 Investment Feasibility Analysis
5.4 Pricing Analysis
Chapter 6. Global Dry Eye Syndrome Market, by Type
6.1 Introduction
6.2 Evaporative Dry Eye Syndrome
Market Estimates & Forecast, 2020 – 2027
6.3 Aqueous Dry Eye Syndrome
Market Estimates & Forecast, 2020 – 2027
Chapter 7. Global Dry Eye Syndrome Market, by Diagnosis
7.1 Introduction
7.2 Schirmer Test
Market Estimates & Forecast, 2020 – 2027
7.3 Eye Exam
Market Estimates & Forecast, 2020 – 2027
7.4 Others
Chapter 8. Global Dry Eye Syndrome Market, by Treatment
8.1 Introduction
8.2 Nutritional Supplements
Market Estimates & Forecast, 2020 – 2027
8.3 Serum Eye Drops
Market Estimates & Forecast, 2020 – 2027
8.4 Lubricant Eye Drops
Market Estimates & Forecast, 2020 – 2027
8.4.1 Oily Tear Eye Drops
8.4.2 Ointments
8.4.3 Preservative-Free drops
8.4.4 Others
8.5 Anti-Inflammatory Drugs Segments
Market Estimates & Forecast, 2020 – 2027
8.5.1 Tetracyclines
8.5.2 Corticosteroids
8.5.3 Others
8.6 Surgery
Market Estimates & Forecast, 2020 – 2027
8.6.1 Punctal Occlusion
8.6.2 Intense Pulsed Light Therapy
8.6.3 Others
8.7 Others
Chapter 9 Global Dry Eye Syndrome Market, by Distribution Channel
9.1 Introduction
9.2 Hospital pharmacies
Market Estimates & Forecast, 2020 – 2027
9.3 Retail pharmacies
Market Estimates & Forecast, 2020 – 2027
9.4 Online Pharmacies
Market Estimates & Forecast, 2020 – 2027
9.5 Others
Chapter 10 Global Dry Eye Syndrome Market, by End User
10.1 Introduction
10.2 Hospitals
Market Estimates & Forecast, 2020 – 2027
10.3 Clinics
Market Estimates & Forecast, 2020 – 2027
10.4 Home Care
Market Estimates & Forecast, 2020 – 2027
10.5 Others
Chapter 11. Global Dry Eye Syndrome Market, by Region
11.1 Introduction
11.2 America
11.2.1 North America
11.2.1.1 U.S.
11.2.1.2 Canada
11.2.2 South America
11.3 Europe
11.3.1 Western Europe
11.3.1.1 Germany
11.3.1.2 France
11.3.1.3 Italy
11.3.1.4 Spain
11.3.1.5 U.K
11.3.1.6 Rest of Western Europe
11.3.2 Eastern Europe
11.4 Asia Pacific
11.4.1 Japan
11.4.2 China
11.4.3 India
11.4.4 Australia
11.4.5 Republic of Korea
11.4.6 Rest of Asia Pacific
11.5 The Middle East & Africa
11.5.1 United Arab Emirates
11.5.2 Saudi Arabia
11.5.3 Oman
11.5.4 Kuwait
11.5.5 Qatar
11.5.6 Rest of the The Middle East & Africa
Chapter 12 Company Landscape
12.1 Introduction
12.2 Market Share Analysis
12.3 Key Development & Strategies
12.3.1 Key Developments
Chapter 13 Company Profiles
13.1 Allergan
13.1.1 Company Overview
13.1.2 Product Overview
13.1.3 Financials
13.1.4 Key Developments
13.1.5 SWOT Analysis
13.2 Novartis AG
13.2.1 Company Overview
13.2.2 Product Overview
13.2.3 Financial Overview
13.2.4 Key Developments
13.2.5 SWOT Analysis
13.3 Otsuka Pharmaceutical Co. Ltd.
13.3.1 Company Overview
13.3.2 Product Overview
13.3.3 Financial Overview
13.3.4 Key Development
13.3.5 SWOT Analysis
13.4 Valent Pharmaceuticals
13.4.1 Company Overview
13.4.2 Product/Business Segment Overview
13.4.3 Financial Overview
13.4.4 Key Development
13.4.5 SWOT Analysis
13.5 Johnson and Johnson Vision
13.5.1 Company Overview
13.5.2 Product Overview
13.5.3 Financial overview
13.5.4 Key Developments
13.5.5 SWOT Analysis
13.6 Acadia Pharmaceutical
13.6.1 Company Overview
13.6.2 Product Overview
13.6.3 Financial Overview
13.6.4 Key Developments
13.6.5 SWOT Analysis
13.7 Allostera Pharma
13.7.1 Overview
13.7.2 Product Overview
13.7.3 Financials
13.7.4 Key Developments
13.7.5 SWOT Analysis
13.8 I-Med Pharma Inc.
13.8.1 Overview
13.8.2 Product Overview
13.8.3 Financials
13.8.4 Key Developments
13.8.5 SWOT Analysis
13.9 Santen Pharmaceuticals Co. Ltd.
13.9.1 Overview
13.9.2 Product Overview
13.9.3 Financials
13.9.4 Key Developments
13.9.5 SWOT Analysis
13.10 AFT pharmaceuticals
13.10.1 Overview
13.10.2 Product Overview
13.10.3 Financials
13.10.4 Key Developments
13.10.5 SWOT Analysis
13.11 Novaliq GmBh
13.11.1 Overview
13.11.2 Product Overview
13.11.3 Financials
13.11.4 Key Developments
13.11.5 SWOT Analysis
13.12 Auven therapeutics
13.12.1 Overview
13.12.2 Product Overview
13.12.3 Financials
13.12.4 Key Developments
13.12.5 SWOT Analysis
13.13 Others
Chapter 14 MRFR Conclusion
14.1 Key Findings
14.1.1 From CEO’s View Point
14.1.2 Unmet Needs of the Market
14.2 Key Companies to Watch
14.3 Prediction of Dry Eye Syndrome Industry
Chapter 15 Appendix
LIST OF TABLES
Table 1 Dry Eye Syndrome Industry Synopsis, 2020 – 2027
Table 2 Global Dry Eye Syndrome Market Estimates and Forecast, 2020 – 2027, (USD Million)
Table 3 Global Dry Eye Syndrome Market by Region, 2020 – 2027, (USD Million)
Table 4 Global Dry Eye Syndrome Market by Type, 2020 – 2027, (USD Million)
Table 5 Global Dry Eye Syndrome Market by Diagnosis, 2020 – 2027, (USD Million)
Table 6 Global Dry Eye Syndrome Market by Treatment, 2020 – 2027, (USD Million)
Table 7 Global Dry Eye Syndrome Market by Distribution Channel, 2020 – 2027, (USD Million)
Table 8 Global Dry Eye Syndrome Market by End User, 2020 – 2027, (USD Million)
Table 9 North America Dry Eye Syndrome Market by Type, 2020 – 2027, (USD Million)
Table 10 North America Dry Eye Syndrome Market by Diagnosis, 2020 – 2027, (USD Million)
Table 11 North America Dry Eye Syndrome Market by Treatment, 2020 – 2027, (USD Million)
Table 12 North America Dry Eye Syndrome Market by Distribution Channel, 2020 – 2027, (USD Million)
Table 13 North America Dry Eye Syndrome Market by End User, 2020 – 2027, (USD Million)
Table 14 US Dry Eye Syndrome Market by Type, 2020 – 2027, (USD Million)
Table 15 US Dry Eye Syndrome Market by Diagnosis, 2020 – 2027, (USD Million)
Table 16 US Dry Eye Syndrome Market by Treatment, 2020 – 2027, (USD Million)
Table 17 US Dry Eye Syndrome Market by Distribution Channel, 2020 – 2027, (USD Million)
Table 18 US Dry Eye Syndrome Market by End User, 2020 – 2027, (USD Million)
Table 19 Canada Dry Eye Syndrome Market by Type, 2020 – 2027, (USD Million)
Table 20 Canada Dry Eye Syndrome Market by Diagnosis, 2020 – 2027, (USD Million)
Table 21 Canada Dry Eye Syndrome Market by Treatment, 2020 – 2027, (USD Million)
Table 22 Canada Dry Eye Syndrome Market by Distribution Channel, 2020 – 2027, (USD Million)
Table 23 Canada Dry Eye Syndrome Market by End User, 2020 – 2027, (USD Million)
Table 24 South America Dry Eye Syndrome Market by Type, 2020 – 2027, (USD Million)
Table 25 South America Dry Eye Syndrome Market by Diagnosis, 2020 – 2027, (USD Million)
Table 26 South America Dry Eye Syndrome Market by Treatment, 2020 – 2027, (USD Million)
Table 27 South America Dry Eye Syndrome Market by Distribution Channel, 2020 – 2027, (USD Million)
Table 28 South America Dry Eye Syndrome Market by End User, 2020 – 2027, (USD Million)
Table 29 Europe Dry Eye Syndrome Market by Type, 2020 – 2027, (USD Million)
Table 30 Europe Dry Eye Syndrome Market by Diagnosis, 2020 – 2027, (USD Million)
Table 31 Europe Dry Eye Syndrome Market by Treatment, 2020 – 2027, (USD Million)
Table 32 Europe Dry Eye Syndrome Market by Distribution Channel, 2020 – 2027, (USD Million)
Table 33 Europe Dry Eye Syndrome Market by End User, 2020 – 2027, (USD Million)
Table 34 Western Dry Eye Syndrome Europe Market by Type, 2020 – 2027, (USD Million)
Table 35 Western Europe Dry Eye Syndrome Market by Diagnosis, 2020 – 2027, (USD Million)
Table 36 Western Europe Dry Eye Syndrome Market by Treatment, 2020 – 2027, (USD Million)
Table 37 Western Europe Dry Eye Syndrome Market by Distribution Channel, 2020 – 2027, (USD Million)
Table 38 Western Europe Dry Eye Syndrome Market by End User, 2020 – 2027, (USD Million)
Table 39 Eastern Europe Dry Eye Syndrome Market by Type, 2020 – 2027, (USD Million)
Table 40 Eastern Europe Dry Eye Syndrome Market by Diagnosis, 2020 – 2027, (USD Million)
Table 41 Eastern Europe Dry Eye Syndrome Market by Treatment, 2020 – 2027, (USD Million)
Table 42 Eastern Europe Dry Eye Syndrome Market by Distribution Channel, 2020 – 2027, (USD Million)
Table 43 Eastern Europe Dry Eye Syndrome Market by End User, 2020 – 2027, (USD Million)
Table 44 Asia Pacific Dry Eye Syndrome Market by Type, 2020 – 2027, (USD Million)
Table 45 Asia Pacific Dry Eye Syndrome Market by Diagnosis, 2020 – 2027, (USD Million)
Table 46 Asia Pacific Dry Eye Syndrome Market by Treatment, 2020 – 2027, (USD Million)
Table 47 Asia Pacific Dry Eye Syndrome Market by Distribution Channel, 2020 – 2027, (USD Million)
Table 48 Asia Pacific Dry Eye Syndrome Market by End User, 2020 – 2027, (USD Million)
Table 49 The Middle East & Africa Dry Eye Syndrome Market by Type, 2020 – 2027, (USD Million)
Table 50 The Middle East & Africa Dry Eye Syndrome Market by Diagnosis, 2020 – 2027, (USD Million)
Table 51 The Middle East & Africa Dry Eye Syndrome Market by Treatment, 2020 – 2027, (USD Million)
Table 52 The Middle East & Africa Dry Eye Syndrome Market by Distribution Channel, 2020 – 2027, (USD Million)
Table 53 The Middle East & Africa Dry Eye Syndrome Market by End User, 2020 – 2027, (USD Million)
LIST OF FIGURES
Figure 1 Research Process
Figure 2 Segmentation for Global Dry Eye Syndrome Market
Figure 3 Segmentation Market Dynamics for Global Dry Eye Syndrome Market
Figure 4 Global Dry Eye Syndrome Market Share, by Type 2020
Figure 5 Global Dry Eye Syndrome Market Share, by Diagnosis 2020
Figure 6 Global Dry Eye Syndrome Market Share, by Treatment 2020
Figure 7 Global Dry Eye Syndrome Market Share, by Distribution Channel 2020
Figure 8 Global Dry Eye Syndrome Market Share, by End User, 2020
Figure 9 Global Dry Eye Syndrome Market Share, by Region, 2020
Figure 10 North America Dry Eye Syndrome Market Share, by Country, 2020
Figure 11 Europe Dry Eye Syndrome Market Share, by Country, 2020
Figure 12 Asia Pacific Dry Eye Syndrome Market Share, by Country, 2020
Figure 13 The Middle East & Africa Dry Eye Syndrome Market Share, by Country, 2020
Figure 14 Global Dry Eye Syndrome Market: Company Share Analysis, 2020 (%)
Figure 15 Allergan: Key Financials
Figure 16 Allergan: Segmental Revenue
Figure 17 Allergan: Geographical Revenue
Figure 18 Novartis AG: Key Financials
Figure 19 Novartis AG: Segmental Revenue
Figure 20 Novartis AG: Geographical Revenue
Figure 21 Otsuka Pharmaceutical Co. Ltd.: Key Financials
Figure 22 Otsuka Pharmaceutical Co. Ltd.: Segmental Revenue
Figure 23 Otsuka Pharmaceutical Co. Ltd.: Geographical Revenue
Figure 24 Valent Pharmaceuticals: Key Financials
Figure 25 Valent Pharmaceuticals: Segmental Revenue
Figure 26 Valent Pharmaceuticals: Geographical Revenue
Figure 27 Johnson and Johnson Vision: Key Financials
Figure 28 Johnson and Johnson Vision: Segmental Revenue
Figure 29 Johnson and Johnson Vision: Geographical Revenue
Figure 30 Acadia Pharmaceutical: Key Financials
Figure 31 Acadia Pharmaceutical: Segmental Revenue
Figure 32 Acadia Pharmaceutical: Geographical Revenue
Figure 33 Allostera Pharma: Key Financials
Figure 34 Allostera Pharma: Segmental Revenue
Figure 35 Allostera Pharma: Geographical Revenue
Figure 36 I-Med Pharma Inc.: Key Financials
Figure 37 I-Med Pharma Inc.: Segmental Revenue
Figure 38 I-Med Pharma Inc.: Geographical Revenue
Figure 39 Santen Pharmaceuticals Co. Ltd.: Key Financials
Figure 40 Santen Pharmaceuticals Co. Ltd.: Segmental Revenue
Figure 41 Santen Pharmaceuticals Co. Ltd.: Geographical Revenue
Figure 42 AFT pharmaceuticals: Key Financials
Figure 43 AFT pharmaceuticals: Segmental Revenue
Figure 44 AFT pharmaceuticals: Geographical Revenue
Figure 45 Novaliq GmBh: Key Financials
Figure 46 Novaliq GmBh: Segmental Revenue
Figure 47 Novaliq GmBh: Geographical Revenue
Figure 48 Auven therapeutics: Key Financials
Figure 49 Auven therapeutics: Segmental Revenue
Figure 50 Auven therapeutics: Geographical Revenue
